Drugs / Friulimicin B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00492271 | Jun → Sep 2007 | staphylococcal infection | MerLion Pharmaceuticals GmbH | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Friulimicin B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00492271 ↗ |
| Known as | Friulimycin b | ChEMBL registry synonym — accepted as the source's own label CHEMBL1688547 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL1688547 ↗ |
| Route | Intravenous | “Intravenous, once daily, single dose” NCT00492271 ↗ |